Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

855
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
855
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

1.0K
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.0K
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

589
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
589
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

513
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
513
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

462
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
462
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

788
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
788

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Outcomes and Acute Exacerbation Incidence in Combined Pulmonary Fibrosis and Emphysema.

Respirology (Carlton, Vic.)·2026
Same author

Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial.

American journal of respiratory and critical care medicine·2026
Same author

Clinical Usage of High-Flow Nasal Cannula Across Disease Categories and Care Settings: A Nationwide Cohort Study in Japan.

Respiratory care·2026
Same author

Simultaneous estimation of sleep duration and sleep apnea-hypopnea using millimeter-wave radar.

Sleep and biological rhythms·2026
Same author

Correction: Non-constraining and non-contact monitoring of respiratory rate at awake and apnea and hypopnea during sleep using a millimeter wave radar.

Sleep and biological rhythms·2026
Same author

Efficacy and safety of RApid PrednIsolone Dose reduction for acute exacerbation of Idiopathic Pulmonary Fibrosis (RAPID-IPF Trial): a study protocol for a randomised controlled trial.

BMJ open respiratory research·2026

Related Experiment Video

Updated: Jan 16, 2026

Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS
08:12

Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS

Published on: November 26, 2018

10.5K

PaO2/FIO2-Based Stratification Discriminates Treatment Failure in Nonintubated Subjects With ARDS.

Masaaki Sakuraya1,2, Kazuma Nagata3, Toshiki Yokoyama4

  • 1Dr. Sakuraya is affiliated with Department of Emergency and Intensive Care Medicine, JA Hiroshima General Hospital, Hatsukaichi, Japan.

Respiratory Care
|September 26, 2025
PubMed
Summary

The PaO2/FiO2 ratio helps predict treatment failure in nonintubated patients with ARDS. Continuous Positive Airway Pressure (CPAP) may be more effective than High-Flow Nasal Cannula (HFNC) for predicting outcomes.

Keywords:
acute respiratory distress syndromecontinuous positive airway pressurehigh-flow nasal cannulahypoxemic respiratory failureoxygenationseverity

More Related Videos

Author Spotlight: Exploring Venous Waveforms for Non-Invasive Respiratory Monitoring in Pigs
04:10

Author Spotlight: Exploring Venous Waveforms for Non-Invasive Respiratory Monitoring in Pigs

Published on: March 8, 2024

1.8K
Lavage-induced Surfactant Depletion in Pigs As a Model of the Acute Respiratory Distress Syndrome ARDS
07:20

Lavage-induced Surfactant Depletion in Pigs As a Model of the Acute Respiratory Distress Syndrome ARDS

Published on: September 7, 2016

11.6K

Related Experiment Videos

Last Updated: Jan 16, 2026

Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS
08:12

Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS

Published on: November 26, 2018

10.5K
Author Spotlight: Exploring Venous Waveforms for Non-Invasive Respiratory Monitoring in Pigs
04:10

Author Spotlight: Exploring Venous Waveforms for Non-Invasive Respiratory Monitoring in Pigs

Published on: March 8, 2024

1.8K
Lavage-induced Surfactant Depletion in Pigs As a Model of the Acute Respiratory Distress Syndrome ARDS
07:20

Lavage-induced Surfactant Depletion in Pigs As a Model of the Acute Respiratory Distress Syndrome ARDS

Published on: September 7, 2016

11.6K

Area of Science:

  • Critical Care Medicine
  • Respiratory Medicine
  • Pulmonary Diseases

Background:

  • The new global definition of Acute Respiratory Distress Syndrome (ARDS) applies to nonintubated patients receiving High-Flow Nasal Cannula (HFNC).
  • Stratification using the PaO2/FiO2 ratio for HFNC in ARDS requires validation.
  • Differences in oxygenation assessment between HFNC and Continuous Positive Airway Pressure (CPAP) for predicting ARDS outcomes are unclear.

Purpose of the Study:

  • To investigate differences in oxygenation assessment between HFNC and CPAP for predicting treatment failure in nonintubated ARDS patients.
  • To evaluate the validity of PaO2/FiO2 stratification for patients on HFNC.
  • To compare the discriminative performance of PaO2/FiO2 for treatment failure between HFNC and CPAP.

Main Methods:

  • Post hoc analysis of a multi-center randomized controlled trial in Japan.
  • Subjects with PaO2/FiO2 < 300 on CPAP were assigned to HFNC or continued CPAP.
  • Stratification into mild, moderate, and severe hypoxemia based on PaO2/FiO2 levels during CPAP.
  • Treatment failure (intubation or in-hospital death) was the primary outcome.
  • Area Under the Receiver Operating Characteristic Curve (AUROC) evaluated device discriminative performance.

Main Results:

  • Treatment failure rates increased with hypoxemia severity: mild (3.2%), moderate (25.0%), and severe (50.0%).
  • Worsened oxygenation after 30 minutes occurred in 44.7% of HFNC patients versus 2.6% of CPAP patients (P < .001).
  • HFNC showed a lower AUROC for PaO2/FiO2 predicting treatment failure (0.66) compared to CPAP (0.82, P = .041).

Conclusions:

  • PaO2/FiO2-based stratification can aid in predicting treatment failure for nonintubated ARDS patients.
  • Variability in oxygenation assessment due to respiratory support devices necessitates thorough evaluation.
  • CPAP may demonstrate superior predictive performance for treatment failure compared to HFNC.